{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:46:11Z","timestamp":1748972771496,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T00:00:00Z","timestamp":1600128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T00:00:00Z","timestamp":1600128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s12325-020-01491-y","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T16:03:59Z","timestamp":1600185839000},"page":"4720-4729","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Open-Label Assessment of the Effects of Itraconazole and Rifampicin on Balovaptan Pharmacokinetics in Healthy Volunteers"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4918-7828","authenticated-orcid":false,"given":"Michael G. M.","family":"Derks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Wandel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart K.","family":"Bolt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Meyenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,15]]},"reference":[{"key":"1491_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.pharmthera.2018.05.007","volume":"190","author":"SR Sharma","year":"2018","unstructured":"Sharma SR, Gonda X, Tarazi FI. Autism spectrum disorder: classification, diagnosis and therapy. Pharmacol Ther. 2018;190:91\u2013104.","journal-title":"Pharmacol Ther"},{"key":"1491_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss6706a1","volume":"67","author":"J Baio","year":"2018","unstructured":"Baio J, Wiggins L, Christensen DL, et al. Prevalence of autism spectrum disorder among children aged 8 years\u2014autism and developmental disabilities monitoring network, 11 sites, United States, 2014. MMWR Surveill Summ. 2018;67:1\u201323.","journal-title":"MMWR Surveill Summ"},{"key":"1491_CR3","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1192\/bjp.bp.115.174649","volume":"209","author":"TS Brugha","year":"2016","unstructured":"Brugha TS, Spiers N, Bankart J, et al. Epidemiology of autism in adults across age groups and ability levels. Br J Psychiatry. 2016;209:498\u2013503.","journal-title":"Br J Psychiatry"},{"key":"1491_CR4","first-page":"389","volume":"40","author":"S LeClerc","year":"2015","unstructured":"LeClerc S, Easley D. Pharmacological therapies for autism spectrum disorder: a review. P T. 2015;40:389\u201397.","journal-title":"P T"},{"key":"1491_CR5","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S1043-2760(00)00304-0","volume":"11","author":"M Birnbaumer","year":"2000","unstructured":"Birnbaumer M. Vasopressin receptors. Trends Endocrinol Metab. 2000;11:406\u201310.","journal-title":"Trends Endocrinol Metab"},{"key":"1491_CR6","doi-asserted-by":"publisher","first-page":"7807","DOI":"10.1073\/pnas.0600875103","volume":"103","author":"TA Koshimizu","year":"2006","unstructured":"Koshimizu TA, Nasa Y, Tanoue A. V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity. Proc Natl Acad Sci USA. 2006;103:7807\u201312.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3\u20134","key":"1491_CR7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.yfrne.2004.09.001","volume":"25","author":"M Engelmann","year":"2004","unstructured":"Engelmann M, Landgraf R, Wotjak CT. The hypothalamic-neurohypophysial system regulates the hypothalamic-pituitary-adrenal axis under stress: an old concept revisited. Front Neuroendocrinol. 2004;25(3\u20134):132\u201349.","journal-title":"Front Neuroendocrinol"},{"key":"1491_CR8","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3389\/fendo.2017.00356","volume":"8","author":"CS Carter","year":"2017","unstructured":"Carter CS. The oxytocin-vasopressin pathway in the context of love and fear. Front Endocrinol (Lausanne). 2017;8:356.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1491_CR9","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1152\/physrev.00035.2011","volume":"92","author":"T Koshimizu","year":"2012","unstructured":"Koshimizu T, Nakamura K, Egashira N, Hiroyama M, Nonoguchi H, Tanoue A. Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol Rev. 2012;92:1813\u201364.","journal-title":"Physiol Rev"},{"key":"1491_CR10","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.neuron.2012.09.025","volume":"76","author":"R Stoop","year":"2012","unstructured":"Stoop R. Neuromodulation by oxytocin and vasopressin. Neuron. 2012;76:142\u201359.","journal-title":"Neuron"},{"key":"1491_CR11","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nrn3044","volume":"12","author":"A Meyer-Lindenberg","year":"2011","unstructured":"Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat Rev Neurosci. 2011;12:524\u201338.","journal-title":"Nat Rev Neurosci"},{"key":"1491_CR12","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1098\/rstb.2006.1939","volume":"361","author":"EA Hammock","year":"2006","unstructured":"Hammock EA, Young LJ. Oxytocin, vasopressin and pair bonding: implications for autism. Philos Trans R Soc Lond B Biol Sci. 2006;361:2187\u201398.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"1491_CR13","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/sj.mp.4001125","volume":"7","author":"SJ Kim","year":"2002","unstructured":"Kim SJ, Young LJ, Gonen D. Transmission disequilibrium testing of arginine vasopressin receptor 1A (AVPR1A) polymorphisms in autism. Mol Psychiatry. 2002;7:503\u20137.","journal-title":"Mol Psychiatry"},{"key":"1491_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13229-017-0161-9","volume":"8","author":"SY Yang","year":"2017","unstructured":"Yang SY, Kim SA, Hur GM, Park M, Park JE, Yoo HJ. Replicative genetic association study between functional polymorphisms in AVPR1A and social behavior scales of autism spectrum disorder in the Korean population. Mol Autism. 2017;8:44.","journal-title":"Mol Autism"},{"key":"1491_CR15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.neulet.2010.05.050","volume":"479","author":"SY Yang","year":"2010","unstructured":"Yang SY, Cho SC, Yoo HJ, et al. Association study between single nucleotide polymorphisms in promoter region of AVPR1A and Korean autism spectrum disorders. Neurosci Lett. 2010;479:197\u2013200.","journal-title":"Neurosci Lett"},{"key":"1491_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2040-2392-2-3","volume":"2","author":"KE Tansey","year":"2011","unstructured":"Tansey KE, Hill MJ, Cochrane LE, Gill M, Anney RJ, Gallagher L. Functionality of promoter microsatellites of arginine vasopressin receptor 1A (AVPR1A): implications for autism. Mol Autism. 2011;2:3.","journal-title":"Mol Autism"},{"key":"1491_CR17","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/sj.mp.4001812","volume":"11","author":"N Yirmiya","year":"2006","unstructured":"Yirmiya N, Rosenberg C, Levi S, et al. Association between the arginine vasopressin 1a receptor (AVPR1a) gene and autism in a family-based study: mediation by socialization skills. Mol Psychiatry. 2006;11:488\u201394.","journal-title":"Mol Psychiatry"},{"key":"1491_CR18","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1038\/npp.2016.232","volume":"42","author":"D Umbricht","year":"2017","unstructured":"Umbricht D, Del Valle RM, Hollander E, et al. A single dose, randomized, controlled proof-of-mechanism study of a novel vasopressin 1a receptor antagonist (RG7713) in high-functioning adults with autism spectrum disorder. Neuropsychopharmacology. 2017;42:1914\u201323.","journal-title":"Neuropsychopharmacology."},{"key":"1491_CR19","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1021\/acs.jmedchem.9b01478","volume":"63","author":"P Schnider","year":"2020","unstructured":"Schnider P, Bissantz C, Bruns A, et al. Discovery of balovaptan, a vasopressin 1a receptor antagonist for the treatment of autism spectrum disorder. J Med Chem. 2020;63:1511\u201325.","journal-title":"J Med Chem"},{"key":"1491_CR20","doi-asserted-by":"crossref","unstructured":"Derks M, Lennon-Chrimes S, Guenther A, et al. Safety, tolerability, pharmacokinetics and metabolism of balovaptan, a selective vasopressin 1a antagonist, in healthy subjects. 32nd European College of Neuropsychopharmacology Congress. 2020;Poster P.210.","DOI":"10.1016\/j.euroneuro.2019.09.253"},{"key":"1491_CR21","doi-asserted-by":"publisher","first-page":"7838","DOI":"10.1126\/scitranslmed.aat7838","volume":"11","author":"F Bolognani","year":"2019","unstructured":"Bolognani F, Del Valle RM, Squassante L, et al. A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder. Sci Transl Med. 2019;11:7838.","journal-title":"Sci Transl Med."},{"key":"1491_CR22","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40801-016-0096-z","volume":"3","author":"R Vohra","year":"2016","unstructured":"Vohra R, Madhavan S, Sambamoorthi U, et al. Prescription drug use and polypharmacy among medicaid-enrolled adults with autism: a retrospective cross-sectional analysis. Drugs Real World Outcomes. 2016;3:409\u201325.","journal-title":"Drugs Real World Outcomes"},{"key":"1491_CR23","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1542\/peds.2012-3774","volume":"132","author":"D Spencer","year":"2013","unstructured":"Spencer D, Marshall J, Post B, et al. Psychotropic medication use and polypharmacy in children with autism spectrum disorders. Pediatrics. 2013;132:833\u201340.","journal-title":"Pediatrics"},{"key":"1491_CR24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138:103\u201341.","journal-title":"Pharmacol Ther"},{"key":"1491_CR25","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00216-008-2291-6","volume":"392","author":"UM Zanger","year":"2008","unstructured":"Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics\/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem. 2008;392:1093\u2013108.","journal-title":"Anal Bioanal Chem"},{"key":"1491_CR26","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1126\/science.286.5439.487","volume":"286","author":"WE Evans","year":"1999","unstructured":"Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286:487\u201391.","journal-title":"Science"},{"key":"1491_CR27","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2174\/138920008784220664","volume":"9","author":"SF Zhou","year":"2008","unstructured":"Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 2008;9:310\u201322.","journal-title":"Curr Drug Metab"},{"key":"1491_CR28","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1086\/598327","volume":"48","author":"RJM Br\u00fcggemann","year":"2009","unstructured":"Br\u00fcggemann RJM, Alffenaar JWC, Blijlevens NMA, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009;48:1441\u2013588.","journal-title":"Clin Infect Dis"},{"key":"1491_CR29","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0009-9236(01)00127-8","volume":"70","author":"Z Wang","year":"2001","unstructured":"Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St John's word (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther. 2001;70:317\u201326.","journal-title":"Clin Pharmacol Ther"},{"key":"1491_CR30","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1517\/17425255.2011.553189","volume":"7","author":"MJ Hanley","year":"2011","unstructured":"Hanley MJ, Cancalon P, Widmer WW, Greenblatt DJ. The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol. 2011;7:267\u201386.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1491_CR31","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1124\/dmd.32.6.587","volume":"32","author":"C Sridar","year":"2004","unstructured":"Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg PF. Sylbin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyl transferases. Drug Metab Dispos. 2004;32:587\u201394.","journal-title":"Drug Metab Dispos"},{"key":"1491_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0009-9236(96)90018-1","volume":"59","author":"JT Backman","year":"1996","unstructured":"Backman JT, Olkkola KT, Neuvonen PJ. Rifampicin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther. 1996;59:7\u201313.","journal-title":"Clin Pharmacol Ther"},{"key":"1491_CR33","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/bcp.12668","volume":"80","author":"DJ Greenblatt","year":"2015","unstructured":"Greenblatt DJ, Harmatz JS. Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450\u20133A in drug-drug interaction studies. Br J Clin Pharmacol. 2015;80:342\u201350.","journal-title":"Br J Clin Pharmacol"},{"key":"1491_CR34","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1001\/archinte.162.9.985","volume":"162","author":"CK Finch","year":"2002","unstructured":"Finch CK, Chrisman CR, Baciewicz AM, Self TH. Rifampin and rifabutin drug interactions. Arch Intern Med. 2002;162:985\u201392.","journal-title":"Arch Intern Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01491-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-020-01491-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01491-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T21:43:04Z","timestamp":1723585384000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-020-01491-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,15]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["1491"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01491-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2020,9,15]]},"assertion":[{"value":"17 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}